| Literature DB >> 31799869 |
Francesco Sardanelli1,2, Andrea Cozzi1, Rubina Manuela Trimboli1, Simone Schiaffino2.
Abstract
OBJECTIVE. The purpose of this article is to describe the risk-benefit balance of contrast-enhanced breast MRI (CE-BMRI) screening. CONCLUSION. CE-BMRI confers risk of effects associated with administration of gadolinium-based contrast agents (GBCAs), including nephrogenic systemic fibrosis and gadolinium retention. The risk-benefit balance of CE-BMRI screening is favorable for carriers of BRCA, TP53, or other deleterious mutations women who have undergone thoracic irradiation; and women at 20% or greater lifetime risk of breast cancer. The balance is uncertain, however, for women at intermediate to average risk. Women must always receive detailed information regarding possible GBCA-associated effects.Entities:
Keywords: MRI; breast neoplasms; contrast media; gadolinium; nephrogenic systemic fibrosis
Mesh:
Substances:
Year: 2019 PMID: 31799869 DOI: 10.2214/AJR.19.21988
Source DB: PubMed Journal: AJR Am J Roentgenol ISSN: 0361-803X Impact factor: 3.959